Scleromyxoedema (lichen myxoedematosus) associated with a paraprotein, IgG 1  of type kappa.
D000328:Adult; D001796:Blood Protein Disorders / Q000209:etiology*; D001797:Blood Protein Electrophoresis; D001853:Bone Marrow / Q000378:metabolism; D001854:Bone Marrow Cells; D001929:Brain Edema / Q000473:pathology; D001996:Bronchopneumonia / Q000209:etiology; D002807:Chondroitin / Q000032:analysis; D046508:Culture Techniques; D005455:Fluorescent Antibody Technique; D006023:Glycoproteins / Q000032:analysis; D006801:Humans; D006820:Hyaluronic Acid / Q000032:analysis; D007122:Immunoelectrophoresis; D007074:Immunoglobulin G / Q000096:biosynthesis*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D009230:Myxedema / Q000150:complications* / Q000188:drug therapy; D012867:Skin / Q000032:analysis / Q000378:metabolism; D012871:Skin Diseases / Q000150:complications* / Q000188:drug therapy; D013464:Sulfuric Acids / Q000032:analysis
D006023:Glycoproteins; D007074:Immunoglobulin G; D013464:Sulfuric Acids; D006820:Hyaluronic Acid; D002807:Chondroitin; D008558:Melphalan